<DOC>
	<DOCNO>NCT01726959</DOCNO>
	<brief_summary>The objective study identify genetic predictor individual methotrexate ( MTX ) response patient rheumatic disease determine genetic metabolomic factor related nutrient metabolism drug transport . The development well genetic predictor individual MTX treatment response would provide invaluable prognostic information prior initiate treatment , would allow appropriate choice therapy , decreased adverse event , efficient dose-escalation drug , ultimate benefit improve effectiveness tolerability rate patient treat MTX autoimmune disease . Despite gold-standard therapy rheumatoid arthritis type chronic autoimmune disease since 1951 , MTX 's efficacy safety profile limit use : MTX discontinue great 50 % patient secondary inefficacy poor tolerability . Upon initial treatment , discontinuation rate approach 12 % drug toxicity , despite prophylactic measure co-administration folic acid . The cause primary failure , secondary failure , adverse event MTX may relate genetic variation dihydrofolate reductase ( DHFR ) gene involve folate metabolism , one-carbon transfer , drug transport . The purpose study identify genetic variation involve methotrexate response may better understand pharmacodynamics MTX metabolism patient rheumatic disease .</brief_summary>
	<brief_title>Prediction Methotrexate Response - A Pilot Study</brief_title>
	<detailed_description />
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Rheumatic Diseases</mesh_term>
	<mesh_term>Collagen Diseases</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>All adult patient ( i.e . &gt; 18 year age ) enrol NorthEast Rheumatology Carolinas Medical Center NorthEast initiate MTX standard treatment particular rheumatic disease , may include ( limited ) condition rheumatoid arthritis , psoriatic arthritis , ankylose spondylitis , inflammatorybowel disease related arthropathy , lupus ( systemic lupus erythematosus , cutaneous lupus erythematosus ) , Sjogren 's syndrome , Behcet 's disease , systemic sclerosis , vasculitides . No prior enrollment study Enrollment initial blood sample collection prior first MTX administration Written inform consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>methotrexate</keyword>
</DOC>